Michael Jaharis
| Michael Jaharis | |
|---|---|
| Born |
July 16, 1928 Evanston, Illinois, US |
| Died | February 17, 2016 (aged 87) New York, New York, US |
| Nationality | American |
| Education |
Carroll University DePaul University College of Law |
| Occupation | Lawyer and Businessman |
| Known for | Founder of Kos Pharmaceuticals Founder of Vatera Healthcare Partners Co-Founder of Arisaph Pharmaceuticals |
| Net worth |
 US$ 2.2 billion (March 2016)
|
| Spouse(s) | Mary Jaharis |
| Children | Two |
Michael Jaharis (July 16, 1928 – February 17, 2016) was an American businessman and philanthropist. He was the founder of Kos Pharmaceuticals and Vatera Healthcare Partners LLC, and co-founder of Arisaph Pharmaceuticals.
Jaharis was born in Evanston, Illinois on July 16, 1928. He graduated from Carroll University and received a J.D. from DePaul University College of Law.
From 1961 to 1972, he worked for Miles Laboratories. In 1972, he became President and CEO of Key Pharmaceuticals, which was essentially an insolvent company known for cold and cough remedies. Under his leadership, the company developed sustained-release Theo-Dur (theophylline), which became the nation's best-selling asthma remedy at the time, and cardiovascular drug Nitro-Dur. Key Pharmaceuticals was sold to Schering-Plough Corporation in 1986. In 1988, he founded Kos Pharmaceuticals, Inc. The company introduced the cholesterol-battling drug Niaspan, which raises HDL levels. Kos Pharmaceuticals was sold to Abbott Labs in 2006 for $4.2 billion.
In 2007, Jaharis co-founded Vatera Healthcare Partners LLC, a New York City-based investment group focused on taking active positions in healthcare companies that develop products for medical needs in a range of therapeutic areas including chronic obstructive pulmonary disease (Pearl Therapeutics), cardio metabolic diseases and cancer (Arisaph Pharmaceuticals), antibiotic resistant bacterial infections (Melinta Therapeutics), and celiac disease (ImmusanT).
...
Wikipedia